Coenzyme Q10 as Treatment for Long Term COVID-19

Aarhus University Hospital121 enrolled

Overview

This study is a randomized, placebo-controlled, double-blinded, cross-over designed clinical trial investigating the effect of high-dose Coenzyme Q10 treatment in subjects with persisting symptoms more than 12 weeks af SARS-CoV-2 infection, Long Term COVID-19 (LTC).

The aim is to investigate the effect of high-dose Coenzyme Q10 on number and severity of self-reported symptoms in patients with Long Term COVID-19. The study will be conducted at the Department of Infectious Diseases, Aarhus University Hospital in the LTC Outpatient Clinic. 120 study participants will be randomized 1:1 to receive placebo or CoQ10 in a dose of 500mg/day for 6 weeks. After a wash-out period of 4 weeks, participants are allocated to the opposite treatment for 6 weeks. The EQ-5D-5L and an LTC-specific questionnaire are completed at baseline and after 6,10,16, and 20 weeks. At each of 5 visits blood samples will be collected from the participants for immunological investigations and assessment of cellular metabolism.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

121

Conditions

Covid19 Long Term Covid19

Interventions

Coenzyme Q10DRUG

Coenzyme Q10 (myoquinon) capsule 100mg, 5 capsules a day.

PlaceboDRUG

A soft gelatin capsule containing soy oil, 5 capsules a day.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age above 18 years. * Able to give informed consent. * History of documented SARS-CoV-2 infection either by RT-PCR or antibody test. * Symptoms related to Long Term COVID-19, defined as being investigated, diagnosed and followed by specialized infectious diseases physicians in the Long Term COVID-19 Outpatient Clinic, Central Region of Denmark, Aarhus University Hospital. * Symptoms not attributable to other co-morbidity/condition. Exclusion Criteria: * Symptoms of acute COVID-19, as defined by The Danish Health Authorities. * Women who are pregnant or breastfeeding, or with a positive pregnancy test as determined by a positive urine beta-human chorionic gonadotropin test during screening * Hypersensitivity to the active ingredient or to any excipient of the medicinal product * Known allergy to soy or peanuts. * Individuals with reduced kidney or liver-function. * Patients in anticoagulant therapy with vitamin K antagonists. * Any condition that, in the Investigator's opinion, will prevent adequate compliance with study therapy.

Locations (1)

Department of Infectious Diseases

Aarhus, Aarhus N, Denmark

Outcomes

Primary Outcomes

Effect of Coenzyme Q10 treatment in Long Term COVID-19 on number of self-reported symptoms of LTC measured by EQ-5D-5L questionnaire.

Number of self-reported symptoms measured by EQ-5D-5L questionnaire.

Time frame: Changes from baseline questionnaire response to questionnaire response after 6 weeks of treatment

Effect of Coenzyme Q10 treatment in Long Term COVID-19 on number of self-reported symptoms of LTC measured by Long Term COVID-specific questionnaire.

Number of self-reported symptoms measured by Long Term COVID-specific questionnaire.

Time frame: Changes from baseline questionnaire response to questionnaire response after 6 weeks of treatment

Effect of Coenzyme Q10 treatment in Long Term COVID-19 on severity (symptoms score) of self-reported symptoms of LTC measured by Long Term COVID-specific questionnaire.

Severity by symptom score of self-reported symptoms measured by Long Term COVID-specific questionnaire. The questionnaire consist of 32 questions with a graduation of 0-4, thus maximum number of points is 128 implying a high number of severe symptoms.

Time frame: Changes from baseline questionnaire response to questionnaire response after 6 weeks of treatment

Effect of Coenzyme Q10 treatment in Long Term COVID-19 on severity (symptoms score) of self-reported symptoms of LTC measured by EQ-5D-5L questionnaire.

Severity by symptom score of self-reported symptoms measured by ED-5Q-5L questionnaire. The questionnaire consist of 5 questions with a graduation of 0-4, thus maximum number of points is 20 implying a high number of severe symptoms.

Time frame: Changes from baseline questionnaire response to questionnaire response after 6 weeks of treatment

Secondary Outcomes

Prolonged effect of Coenzyme Q10 treatment in Long Term COVID-19 on number of self-reported symptoms of LTC measured by Long Term COVID-specific questionnaire.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.